R&D News | pharmaphorum

News

Has trial result burst BMS' Cobenfy bubble?

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial.

News

Data readout puts J&J's bladder cancer drug back on track

New data in non-muscle-invasive bladder cancer (NMIBC) has backed up Johnson & Johnson's faith in its TAR-200 drug candidate.

News

Sky Labs' smart ring tops Apple Watch in AFib comparison

A smart ring developed by South Korean healthtech Sky Labs has outperformed the Apple Watch in a head-to-head comparison.

News

Roche joins the pharma firms planning big US investments

Roche will spend $50bn on manufacturing and R&D facilities in the US, with a pledge to export more medicines from the US than it imports.

News

Woman with breast cancer covering her chest with her hands

Enhertu poised to move first line in HER2+ breast cancer

New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

News

Vials on a conveyor belt - pharma manufacturing

Trodelvy-Keytruda pairing hits the spot in breast cancer

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

Has trial result burst BMS' Cobenfy bubble?

Data readout puts J&J's bladder cancer drug back on track

Sky Labs' smart ring tops Apple Watch in AFib comparison

Roche joins the pharma firms planning big US investments

Enhertu poised to move first line in HER2+ breast cancer

Trodelvy-Keytruda pairing hits the spot in breast cancer

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks